@article{3b16d4ed69ad40568ebb62acc2296804,
title = "Cancer immunotherapy-targeted glypican-3 or neoantigens",
abstract = "Immune checkpoint inhibitors have ushered in a new era in cancer therapy, although other therapies or combinations thereof are still needed for many patients for whom these drugs are ineffective. In this light, we have identified glypican-3 an HLA-24, HLA-A2 restriction peptide with extreme cancer specificity. In this paper, we summarize results from a number of related clinical trials showing that glypican-3 peptide vaccines induce specific CTLs in most patients (UMIN Clinical Trials Registry: UMIN000001395, UMIN000005093, UMIN000002614, UMN000003696, and UMIN000006357). We also describe the current state of personalized cancer immunotherapy based on neoantigens, and assess, based on our own research and experience, the potential of such therapy to elicit cancer regression. Finally, we discuss the future direction of cancer immunotherapy.",
keywords = "cancer vaccine, CAR-transduced T-cell therapy, glypican-3, neoantigen, TCR-transduced T-cell therapy",
author = "Yasuhiro Shimizu and Toshihiro Suzuki and Toshiaki Yoshikawa and Nobuhiro Tsuchiya and Yu Sawada and Itaru Endo and Tetsuya Nakatsura",
note = "Funding Information: National Cancer Center; Health and Labor Science Research Grants for Clinical Research, Japan; Takeda Pharmaceutical Co., Ltd.; Noile-Immune Biotech Inc.; Ono Pharmaceutical Co., Ltd.; BrightPath Biotherapeutics Co., Ltd.; Sysmex Co., Ltd. Funding Information: This study was supported in part by the National Cancer Center Research and Development Fund (25-A-7) and (28-A-8), as well as Health and Labor Science Research Grants for Clinical Research, Japan and joint research funding from Takeda Pharmaceutical Co, Ltd., Noile-Immune Biotech Inc., Ono Pharmaceutical Co., Ltd., BrightPath Biotherapeutics Co., Ltd., and Sysmex Co., Ltd. This study was performed as a part of a research program of the Project for Development of Innovative Research on Cancer Therapeutics (P-Direct), Ministry of Education, Culture, Sports, Science and Technology of Japan and supported by AMED under Grant Number JP15cm0106115h0002 and JP17ck0106204h0002 Funding Information: T. N. is a scientific advisor for Ono Pharmaceutical Co., Ltd. T. N., T. S., and T. Y. are supported by fundamental research funding from Takeda Pharmaceutical Co., Ltd., and BrightPath Biotherapeutics Co., Ltd. T. N. and T. S. are supported by fundamental research funding from Ono Pharmaceutical Co., Ltd., T. N. is supported by fundamental research funding from Noile-Immune Biotech Inc. and Sysmex Co., Ltd. The other authors have no conflict of interest. Publisher Copyright: {\textcopyright} 2017 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.",
year = "2018",
month = mar,
doi = "10.1111/cas.13485",
language = "English",
volume = "109",
pages = "531--541",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "3",
}
